Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 114Neoplasms 28Lung Neoplasms 24Non-Squamous Non-Small Cell Lung Cancer 21Pancreatic Neoplasms 13Colorectal Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lymphoma 3Thoracic Neoplasms 2Solid Tumors 2Recurrence 2Neoplasms by Site 2Lung Diseases 2Familial ependymoma 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Bronchial Neoplasms 2Advanced Solid Tumors 2Vascular Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoking 1Small Cell Lung Carcinoma 1

Interventions

Temozolomide 2Etoposide 2Erlotinib Hydrochloride 2pomalidomide 1dostarlimab 1dinutuximab 1cemiplimab 1bempegaldesleukin 1abemaciclib 1Valacyclovir 1Radiotherapy 1Radiation 1Prodrugs 1Pemetrexed 1ONC206 1Nivolumab 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fentanyl 1Cyclophosphamide 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ependymoma × Erlotinib Hydrochloride × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡